Abstract
Background/Objectives: Insulin-like growth factor-1 receptor (IGF-1R) displays a key role in tumor transformation and metastasis. It also makes tumor cells more resistant to chemotherapy. The aim of this study was to investigate the correlation between IGF-1R and multidrug resistance-associated protein-1 (MRP-1), and the clinical significance of their expression in gastric carcinoma (GC). Methods: IGF-1R and MRP-1 expressed in 113 specimens were detected by immunohistochemistry. The correlation between IGF-1R and MRP-1 expression was determined. In addition, the association of their expression with clinicopathological features and survival data of GC was also analyzed. Results: IGF-1R (75.2%) and MRP-1 (69.0%) were frequently expressed in GC. IGF-1R was associated with tumor size, quantity of stroma, depth of wall invasion, lymph node metastasis, TNM stages and differentiation status of GC (p < 0.05). MRP-1 was associated with tumor size, quantity of stroma, lymph node metastasis, distant metastasis and TNM stages (p < 0.05). IGF-1R over-expression positively correlated with MRP-1 over-expression (rp = 0.39, p < 0.01). IGF-1R and MPR-1 over-expression were correlated with poor prognosis of GC (p < 0.01). 102 patients receiving adjuvant FOLFOX-4 chemotherapy who co-expressed IGF-1R/MRP-1 had poor prognosis (p < 0.05). Conclusions: The levels of co-expression of IGF-1R/MRP-1 in GC may predict the therapeutic effect of chemotherapy and prognosis of GC.
Journal Section:
Original Paper
References
1.
Ito R, Oue N, Yoshida K, Kunimitsu K, Nakayama H, Nakachi K, Yasui W: Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer. Virchows Arch 2005;447:717–722.
[PubMed]
2.
Wu ZY, Li JH, Zhan WH, He YL, Wan J: Effect of lymph node micrometastases on prognosis of gastric carcinoma. World J Gastroenterol 2007;13:4122–4125.
[PubMed]
3.
Buerger C, Groner B: Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling. J Cancer Res Clin Oncol 2003;129:669–675.
[PubMed]
4.
Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB: Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005;205:145–153.
[PubMed]
5.
Pavelic K, Kolak T, Kapitanovic S, Radosevic S, Spaventi S, Kruslin B, Pavelic J: Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol 2003;201:430–438.
[PubMed]
6.
Kiess W, Koepf G, Christiansen H, Blum WF: Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept 1997;72:19–29.
[PubMed]
7.
Liu X, Turbyville T, Fritz A, Whitesell L: Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 1998;58:5432–5438.
[PubMed]
8.
Jiang Y, Rom WN, Yie TA, Chi CX, Tchou-Wong KM: Induction of tumor suppression and glandular differentiation of a549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 1999;18:6071–6077.
[PubMed]
9.
Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blattler WA, Chittenden T, Singh R: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073–5083.
[PubMed]
10.
Baserga R: The IGF-I receptor in cancer research. Exp Cell Res 1999;253:1–6.
[PubMed]
11.
Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472–1489.
[PubMed]
12.
Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004;68:1003–1015.
[PubMed]
13.
Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia N: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005;113:316–328.
[PubMed]
14.
Vasilcanu D, Weng WH, Girnita A, Lui WO, Vasilcanu R, Axelson M, Larsson O, Larsson C, Girnita L: The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene 2006;25:3186–3195.
[PubMed]
15.
Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, Hinoda Y, Lee CT, Nadaf S, Carbone DP, Imai K: Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 2005;54:591–600.
[PubMed]
16.
Lautier D, Canitrot Y, Deeley RG, Cole SP: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 1996;52:967–977.
[PubMed]
17.
Borst P, Elferink RO: Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537–592.
[PubMed]
18.
Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295–1302.
[PubMed]
19.
Fan K, Fan D, Cheng LF, Li C: Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res 2000;20:4809–4814.
[PubMed]
20.
Lacueva FJ, Calpena R, Medrano J, Teruel A, Mayol MJ, Graells ML, Camarasa MV, Perez-Vazquez MT, Ferragut JA: Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53. Cancer 2000;89:21–28.
[PubMed]
21.
Lacueva J, Perez-Ramos M, Soto JL, Oliver I, Andrada E, Medrano J, Perez-Vazquez T, Arroyo A, Carrato A, Ferragut JA, Calpena R: Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas: analysis by immunohistochemistry and real-time quantitative RT-PCR. Histopathology 2005;46:389–395.
[PubMed]
22.
Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.
[PubMed]
23.
Sobin LH, Wittekind C: International Union against Cancer (UICC): TNM classification of malignant tumours, ed 5. New York, John Wiley & Sons, 1997.
24.
Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 2nd English edition. Gastric Cancer 1998;1:10–24.
[PubMed]
25.
Shen H, Fan Y, Yang X, Burczynski FJ, Li P, Gong Y: Increased expression of cystic fibrosis transmembrane conductance regulator in rat liver after common bile duct ligation. J Cell Physiol 2005;203:599–603.
[PubMed]
26.
Ge J, Chen Z, Wu S, Yuan W, Hu B: A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma. Clin Oncol (R Coll Radiol) 2008;20:275–283.
[PubMed]
27.
Pei H, Zhu H, Zeng S, Li Y, Yang H, Shen L, Chen J, Zeng L, Fan J, Li X, Gong Y, Shen H: Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res 2007;6:2495–2501.
[PubMed]
28.
Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB: Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 2002;95:2086–2095.
[PubMed]
29.
Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB: Expression of multidrug resistance-associated protein 1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2002;86:1578–1585.
[PubMed]
30.
Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA Jr, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR: Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006;17:1120–1127.
[PubMed]
31.
Bray F, Sankila R, Ferlay J, Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002;38:99–166.
[PubMed]
32.
Black RJ, Bray F, Ferlay J, Parkin DM: Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075–1107.
[PubMed]
33.
Sun XD, Mu R, Zhou YS, Dai XD, Zhang SW, Huangfu XM, Sun J, Li LD, Lu FZ, Qiao YL: Analysis of mortality rate of stomach cancer and its trend in twenty years in china (in Chinese). Zhonghua Zhong Liu Za Zhi 2004;26:4–9.
[PubMed]
34.
Sun X, Mu R, Zhou Y, Dai X, Qiao Y, Zhang S, Huangfu X, Sun J, Li L, Lu F: 1990–1992 mortality of stomach cancer in China (in Chinese). Zhonghua Zhong Liu Za Zhi 2002;24:4–8.
[PubMed]
35.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–789.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.
